Eton Pharmaceuticals Inc (ETON)
10.75
+0.32
(+3.07%)
USD |
NASDAQ |
Nov 21, 16:00
10.20
-0.55
(-5.12%)
Pre-Market: 08:21
Eton Pharmaceuticals Enterprise Value: 261.60M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 261.60M |
| November 20, 2024 | 253.34M |
| November 19, 2024 | 255.14M |
| November 18, 2024 | 243.00M |
| November 15, 2024 | 242.74M |
| November 14, 2024 | 254.11M |
| November 13, 2024 | 257.73M |
| November 12, 2024 | 220.78M |
| November 11, 2024 | 234.73M |
| November 08, 2024 | 210.71M |
| November 07, 2024 | 207.86M |
| November 06, 2024 | 207.86M |
| November 05, 2024 | 201.40M |
| November 04, 2024 | 199.60M |
| November 01, 2024 | 206.57M |
| October 31, 2024 | 202.70M |
| October 30, 2024 | 208.64M |
| October 29, 2024 | 204.51M |
| October 28, 2024 | 201.40M |
| October 25, 2024 | 193.40M |
| October 24, 2024 | 195.46M |
| October 23, 2024 | 193.91M |
| October 22, 2024 | 200.37M |
| October 21, 2024 | 201.92M |
| October 18, 2024 | 199.60M |
| Date | Value |
|---|---|
| October 17, 2024 | 200.89M |
| October 16, 2024 | 197.01M |
| October 15, 2024 | 201.28M |
| October 14, 2024 | 195.46M |
| October 11, 2024 | 190.55M |
| October 10, 2024 | 186.16M |
| October 09, 2024 | 183.32M |
| October 08, 2024 | 175.05M |
| October 07, 2024 | 172.47M |
| October 04, 2024 | 164.72M |
| October 03, 2024 | 162.39M |
| October 02, 2024 | 137.33M |
| October 01, 2024 | 136.56M |
| September 30, 2024 | 138.88M |
| September 27, 2024 | 136.81M |
| September 26, 2024 | 133.71M |
| September 25, 2024 | 130.87M |
| September 24, 2024 | 135.52M |
| September 23, 2024 | 137.59M |
| September 20, 2024 | 127.00M |
| September 19, 2024 | 139.40M |
| September 18, 2024 | 139.66M |
| September 17, 2024 | 134.75M |
| September 16, 2024 | 129.06M |
| September 13, 2024 | 120.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
40.92M
Minimum
Sep 26 2022
261.60M
Maximum
Nov 21 2024
106.24M
Average
94.49M
Median
Mar 16 2023
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Integra Lifesciences Holdings Corp | 3.304B |
| Elutia Inc | 148.97M |
| Immuneering Corp | 14.86M |
| Journey Medical Corp | 105.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.627M |
| Revenue (Quarterly) | 10.32M |
| Total Expenses (Quarterly) | 9.815M |
| EPS Diluted (Quarterly) | 0.02 |
| Gross Profit Margin (Quarterly) | 61.04% |
| Profit Margin (Quarterly) | 6.07% |
| Earnings Yield | -2.05% |
| Normalized Earnings Yield | -2.046 |